|
1
|
Klimstra DS, Modlin IR, Coppola D, Lloyd
RV and Suster S: The pathologic classification of neuroendocrine
tumors: A review of nomenclature, grading, and staging systems.
Pancreas. 39:707–712. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pusceddu S, Lo Russo G, Macerelli M, Proto
C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L,
Trama A, et al: Diagnosis and management of typical and atypical
lung carcinoids. Crit Rev Oncol Hematol. 100:167–176. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petursdottir A, Sigurdardottir J,
Fridriksson BM, Johnsen A, Isaksson HJ, Hardardottir H, Jonsson S
and Gudbjartsson T: Pulmonary carcinoid tumours: Incidence,
histology, and surgical outcome. A population-based study. Gen
Thorac Cardiovasc Surg. Nov 28–2019.(Epub ahead of print).
|
|
4
|
Bertino EM, Confer PD, Colonna JE, Ross P
and Otterson GA: Pulmonary neuroendocrine/carcinoid tumors: A
review article. Cancer. 115:4434–4441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filosso PL, Ferolla P, Guerrera F, Ruffini
E, Travis WD, Rossi G, Lausi PO and Oliaro A; European Society of
Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering
Committee, : Multidisciplinary management of advanced lung
neuroendocrine tumors. J Thorac Dis. 7 (Suppl 2):S163–S171.
2015.PubMed/NCBI
|
|
6
|
Oberg K, Hellman P, Ferolla P and Papotti
M; ESMO Guidelines Working Group, : Neuroendocrine bronchial and
thymic tumors: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 23 (Suppl 7):vii120–vii123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zatelli MC, Minoia M, Martini C, Tagliati
F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E,
Cavallesco G, et al: Everolimus as a new potential
antiproliferative agent in aggressive human bronchial carcinoids.
Endocr Relat Cancer. 17:719–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swarts DR, Ramaekers FC and Speel EJ:
Molecular and cellular biology of neuroendocrine lung tumors:
Evidence for separate biological entities. Biochim Biophys Acta.
1826:255–271. 2012.PubMed/NCBI
|
|
11
|
Travis WD, Rush W, Flieder DB, Falk R,
Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary
neuroendocrine tumors with clarification of criteria for atypical
carcinoid and its separation from typical carcinoid. Am J surg
Pathol. 22:934–944. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arrigoni MG, Woolner LB and Bernatz PE:
Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg.
64:413–421. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Travis WD: Pathology and diagnosis of
neuroendocrine tumors: Lung neuroendocrine. Thorac Surg Clin.
24:257–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horsch D, Schmid KW, Anlauf M, Darwiche K,
Denecke T, Baum RP, Spitzweg C, Grohé C, Presselt N, Stremmel C, et
al: Neuroendocrine tumors of the bronchopulmonary system (typical
and atypical carcinoid tumors): Current strategies in diagnosis and
treatment. Conclusions of an expert meeting February 2011 in
Weimar, Germany. Oncol Res Treat. 37:266–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pelosi G, Rindi G, Travis WD and Papotti
M: Ki-67 antigen in lung neuroendocrine tumors: Unraveling a role
in clinical practice. J Thorac Oncol. 9:273–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dodt M, Roehr JT, Ahmed R and Dieterich C:
FLEXBAR-flexible barcode and adapter processing for next-generation
sequencing platforms. Biology (Basel). 1:895–905. 2012.PubMed/NCBI
|
|
17
|
Koboldt DC, Zhang Q, Larson DE, Shen D,
McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK:
VarScan 2: Somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res. 22:568–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robinson JT, Thorvaldsdottir H, Wenger AM,
Zehir A and Mesirov JP: Variant review with the integrative
genomics viewer. Cancer Res. 77:e31–e34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thorvaldsdottir H, Robinson JT and Mesirov
JP: Integrative Genomics Viewer (IGV): High-performance genomics
data visualization and exploration. Brief Bioinform. 14:178–192.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robinson JT, Thorvaldsdottir H, Winckler
W, Guttman M, Lander ES, Getz G and Mesirov JP: Integrative
genomics viewer. Nat Biotechnol. 29:24–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lohmann DR, Fesseler B, Pütz B, Reich U,
Böhm J, Präuer H, Wünsch PH and Höfler H: Infrequent mutations of
the p53 gene in pulmonary carcinoid tumors. Cancer Res.
53:5797–5801. 1993.PubMed/NCBI
|
|
23
|
Meisinger QC, Klein JS, Butnor KJ,
Gentchos G and Leavitt BJ: CT features of peripheral pulmonary
carcinoid tumors. AJR Am J Roentgenol. 197:1073–1080. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schrevens L, Vansteenkiste J, Deneffe G,
De Leyn P, Verbeken E, Vandenberghe T and Demedts M:
Clinical-radiological presentation and outcome of surgically
treated pulmonary carcinoid tumours: A long-term single institution
experience. Lung Cancer. 43:39–45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pavel M, O'Toole D, Costa F, Capdevila J,
Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, et
al: ENETS consensus guidelines update for the management of distant
metastatic disease of intestinal, pancreatic, bronchial
neuroendocrine neoplasms (NEN) and NEN of unknown primary site.
Neuroendocrinology. 103:172–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Caplin ME, Baudin E, Ferolla P, Filosso P,
Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, et
al: Pulmonary neuroendocrine (carcinoid) tumors: European
Neuroendocrine Tumor Society expert consensus and recommendations
for best practice for typical and atypical pulmonary carcinoids.
Ann Oncol. 26:1604–1620. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lou G, Yu X and Song Z: Molecular
profiling and survival of completely resected primary pulmonary
neuroendocrine carcinoma. Clin Lung Cancer. 18:e197–e201. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vollbrecht C, Werner R, Walter RF,
Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger
T, Schmid KW, et al: Mutational analysis of pulmonary tumours with
neuroendocrine features using targeted massive parallel sequencing:
A comparison of a neglected tumour group. Br J Cancer.
113:1704–1711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Armengol G, Sarhadi VK, Ronty M, Tikkanen
M, Knuuttila A and Knuutila S: Driver gene mutations of
non-small-cell lung cancer are rare in primary carcinoids of the
lung: NGS study by ion Torrent. Lung. 193:303–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Voortman J, Harada T, Chang RP, Killian
JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y and
Giaccone G: Detection and therapeutic implications of c-Met
mutations in small cell lung cancer and neuroendocrine tumors. Curr
Pharm Des. 19:833–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Capodanno A, Boldrini L, Ali G,
Pelliccioni S, Mussi A and Fontanini G:
Phosphatidylinositol-3-kinase α catalytic subunit gene somatic
mutations in bronchopulmonary neuroendocrine tumours. Oncol Rep.
28:1559–1566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
D'Alessandro V, Muscarella LA, la Torre A,
Bisceglia M, Parrella P, Scaramuzzi G, Storlazzi CT, Trombetta D,
Kok K, De Cata A, et al: Molecular analysis of the HuD gene in
neuroendocrine lung cancers. Lung Cancer. 67:69–75. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Snabboon T, Plengpanich W, Siriwong S,
Wisedopas N, Suwanwalaikorn S, Khovidhunkit W and Shotelersuk V: A
novel germline mutation, 1793delG, of the MEN1 gene underlying
multiple endocrine neoplasia type 1. Jpn J Clin Oncol. 35:280–282.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sugio K, Osaki T, Oyama T, Takenoyama M,
Hanagiri T, Morita M, Yamazaki K, Nagashima A, Nakahashi H, Maehara
Y and Yasumoto K: Genetic alteration in carcinoid tumors of the
lung. Ann Thorac Cardiovasc Surg. 9:149–154. 2003.PubMed/NCBI
|
|
35
|
Couce ME, Bautista D, Costa J and Carter
D: Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine
neoplasms. Diagn Mol Pathol. 8:71–79. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sagawa M, Saito Y, Fujimura S and Linnoila
RI: K-ras point mutation occurs in the early stage of
carcinogenesis in lung cancer. Br J Cancer. 77:720–723. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Debelenko LV, Brambilla E, Agarwal SK,
Swalwell JI, Kester MB, Lubensky IA, Zhuang Z, Guru SC, Manickam P,
Olufemi SE, et al: Identification of MEN1 gene mutations in
sporadic carcinoid tumors of the lung. Hum Mol Genet. 6:2285–2290.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hiyama K, Hasegawa K, Ishioka S, Takahashi
N and Yamakido M: An atypical carcinoid tumor of the lung with
mutations in the p53 gene and the retinoblastoma gene. Chest.
104:1606–1607. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Walter RF, Vollbrecht C, Christoph D,
Werner R, Schmeller J, Flom E, Trakada G, Rapti A, Adamidis V,
Hohenforst-Schmidt W, et al: Massive parallel sequencing and
digital gene expression analysis reveals potential mechanisms to
overcome therapy resistance in pulmonary neuroendocrine tumors. J
Cancer. 7:2165–2172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rossi G, Bertero L, Marchiò C and Papotti
M: Molecular alterations of neuroendocrine tumours of the lung.
Histopathology. 72:142–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Asiedu MK, Thomas CF Jr, Dong J, Schulte
SC, Khadka P, Sun Z, Kosari F, Jen J, Molina J, Vasmatzis G, et al:
Pathways impacted by genomic alterations in pulmonary carcinoid
tumors. Clin Cancer Res. 24:1691–1704. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maennling AE, Tur MK, Niebert M,
Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I
and Hussain AF: Molecular targeting therapy against EGFR family in
breast cancer: Progress and future potentials. Cancers (Basel).
11:E18262019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chughtai S: The nuclear translocation of
insulin-like growth factor receptor and its significance in cancer
cell survival. Cell Biochem Funct. Dec 25–2019.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Salgia R: MET in lung cancer: Biomarker
selection based on scientific rationale. Mol Cancer Ther.
16:555–565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Miettinen M and Lasota J: KIT (CD117): A
review on expression in normal and neoplastic tissues, and
mutations and their clinicopathologic correlation. Appl
Immunohistochem Mol Morphol. 13:205–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
